CopenhagenNovo Nordisk’s CEO admits the Ozempic maker “over-promised.”
Investors are pricing in a patent cliff on its biggest drugs starting next decade.
Semaglutide’s patents are lapsing in India, China, Brazil and Canada, so generic copies reach those markets years before Western patients.
CEO Mike Doustdar has not said when Denmark’s Novo Nordisk plans to rebuild investor confidence beyond the admission.
Sources: Bloomberg Business